ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Weightloss in Menopause

Susan Brian

Coronary CTA for Assessing CAD - Are We There Yet?

Matthew Budoff

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Endocrinology 2024 Year in Review

Hypertension 2025: New Guidelines and Resistant Hypertension

University of Louisville

K. Ferdinand

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Heart Failure: NICE Guideline

Practical GP

F. Florido

Cholesterol Treatment Decisions: Recent Updates to Guidelines and St…

Gary Martin

Tirzepatide Updates

Diana Isaacs

The Deadly Paradox: Current Practice, Driven by Guidelines, Is Not A…

Michael Makover

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Vitamin D Deficiency

Keck School of Medicine of USC

V. Gevorgyan

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

"Pill in Pocket" Anticoagulation for Atrial Fibrillation: Fact, Fict…

Houston Methodist DeBakey Heart and Vascular Center

R. Passman

New Research: Side Effect of GLP1

Susan Brian

ACC 2024 Insights: A Plant-Based Diet

ACC 2024 Insights

N. Barnard

Boost Your Heart Health With the Power of Nutrition

Baystate Health

B. Sarrette

Weight Loss Fads: Where's the Evidence?

Scripps Health

D. Ahn